How Gen AI-Powered Social Media Intelligence Is Reshaping Pharma Conference Strategy

Major medical conferences like ASCO (American Society of Clinical Oncology), ESMO (European Society for Medical Oncology), ADA (American Diabetes Association), and EULAR (European Alliance of Associations for Rheumatology) have long been significant events in the pharma calendar. These forums are strategic platforms where clinical narratives are shaped, scientific advancements revealed, competitive messaging unfolds, new themes added within therapy areas and stakeholder sentiment becomes visible.

In recent years, the digital layer of these conferences has grown in significance. Social media platforms have become real-time mirrors of perception, capturing reactions from healthcare professionals (HCPs), patients, advocacy groups, support groups/associations and competitors. Yet, most pharmaceutical companies still struggle to translate this digital noise into competitive advantage. The core challenge remains: how do you quickly transform from tracking mentions to generating meaningful insights?

Why conventional social media intelligence often misses the mark at medical conferences

Many life sciences teams already monitor social media during major medical events. But most efforts result in dashboards primarily focused on activity metrics such as tweet volumes, trending hashtags, and top influencers. These outputs often fail to deliver insight.

Here’s why.

Volume outpaces analysis

Thousands of posts, comments, and reactions are generated in a matter of days, much faster than most teams can process.

Lack of structure

Conversations differ in terminology, context, relevance, and quality. Without consistent taxonomy, aggregation becomes noisy.

Functional silos

Medical Affairs may track key opinion leader (KOL) narratives, Commercial teams may focus on competitor signals, while Competitive Intelligence may monitor innovation pipelines. Rarely are these views connected.

The result is fragmented understanding, delayed response, and missed opportunities.

How Gen AI enhances social media intelligence during conferences

Generative AI has accelerated the ability to process large-scale conference related conversations. Its capabilities are significant.

However, GenAI models are not inherently pharma-aware to just plug and play. Nuance matters. For instance, a molecule mentioned out of context, a trial result framed without scientific rigor, or a sarcastic tweet misread by a model—these are easy traps for models lacking domain context. And that’s why Gen AI performs best when guided by a strong foundation of domain knowledge and human oversight.

Structuring social media intelligence with medical taxonomies

The effectiveness of social media intelligence hinges on how data is organized. In pharma, generic buckets like “efficacy,” “safety,” or “sentiment” lack depth. Instead, teams must apply a tailored medical taxonomy with therapeutic depth.

This taxonomy should account for:

When applied consistently, this taxonomy becomes a shared language across GenAI models and human analysts. It ensures that surfaced insights are both scientifically grounded and commercially relevant. Most importantly, it enables knowledge reuse across multiple conferences over time.

Connecting the dots: Cross-conference intelligence

Most organizations treat conference insights as one-off outputs, focused only on individual events. But the real strategic value comes from connecting signals across conferences and tracking how narratives evolve over time. When teams link insights from ASCO to ESMO, or ASCO 2023 Vs. 2024, clear patterns start to emerge.

Thought leaders may reinforce or shift their positions across forums; molecules that received limited attention at one event may gain momentum later due to new clinical data or new healthcare situation (sudden spike in incidence); persistent unmet needs such as therapeutic gaps may reappear, paving way for better patient support.

By analyzing these patterns across events, organizations move from reactive monitoring to strategic foresight.

What it takes to extract conference insights from social media intelligence

Many see conference insight extraction as a technology problem. In reality, it’s a multidisciplinary effort that works only when the right expertise comes together. Teams need a strong grasp of therapeutic areas, such as how a trial outcome resonates in first-line versus second-line treatment, or how thought leaders are discussing emerging mechanisms of action. They also need technical fluency to fine-tune/train GenAI models, organize unstructured data, and scale workflows without compromising scientific accuracy.

The ability to turn raw findings into business-relevant insights is just as critical. That means identifying unmet needs, tracking shifts in clinical positioning, or spotting early competitor signals. This translation layer often determines whether insights lead to action or get lost in noise.

Successful teams blend four core strengths:

It’s this fusion of skillsets and tools that helps organizations move beyond surface-level analysis and unlock the true value of social media intelligence at medical conferences.

Leading with social media intelligence

Medical conferences generate a fast-moving stream of digital conversations. Traditional tracking tools often stop at surface-level activity. They miss the deeper signals, i.e. shifts in clinical narratives, changing stakeholder sentiment, and early indicators of competitive movement. Social media intelligence, powered by GenAI and guided by tailored taxonomies, helps teams extract those signals at scale. It turns scattered inputs into strategic insight, helping organizations learn, respond, and build continuity across events.

The real advantage lies in how quickly you can make sense of what’s emerging and act on it. Listening is only the first step. Learning is what will set commercial leaders ahead.

Disclaimer: The views and opinions expressed in this article are solely those of the author and do not necessarily reflect the official position or views of Novo Nordisk. The content herein has been prepared for informational purposes only and does not contain, reference, or disclose any proprietary or confidential information belonging to Novo Nordisk.